The invention relates to an optical method for detecting at least one target molecule (TM) contained in a sample at a determined concentration, which comprises: (a) bringing a sample containing the TM into contact, in a liquid medium, with a solution containing nanoparticles (NPs), the surface of the NPs having been coated or functionalised with at least one type of specific bioreceptor (BR) of the target molecule to be detected (NP-BR), such that the BRs specifically recognise the TM, thus forming conjugates of the NP-BRs with the TMs (NP-BR-TMs); (b) separating the nanoparticles conjugates (NP-BR-TMs and/or NP-BRs) formed in the previous step; (c) bringing the nanoparticles conjugates (NP-BR-TMs and/or NP-BRs) into contact with a sensor surface of an optical transducer that operates by means of reflection and/or transmission, the response of which is based on optical interference, the sensor surface being functionalised by immobilising thereon: (i) the target molecule (TM) or (ii) at least one specific bioreceptor of the target molecule, which may be of the same type (BR) or of another type (BR1); and (d) determining the optical reading on the sensor surface by means of change in the interference response of the optical transducer, caused by change in the real part of the refractive index as a result of the NP conjugates recognised on the sensor surface, and/or by means of change in intensity in the interference response, caused by variation in intensity as a result of dispersion or as a result of variation in the complex part of the refractive index of the NP conjugates, or by means of a combination of both effects amplification in the interference response by refractive index and scattering.

This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

Provided is an approach of predicting a risk of occurrence of anaphylaxis in an infant or a child having food allergy by measuring an antibody titer of an IgE antibody and avidity of the IgE antibody against an allergen in a sample collected from the infant or the child, and predicting the risk of occurrence of anaphylaxis in the infant or the child according to a criterion created on the basis of ROC analysis.

The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.

A method of ionising a sample is disclosed comprising nebulising a sample which includes monoclonal antibody (“mAb”) molecules. A stream of monoclonal antibody droplets or charged droplets is directed so as to impact upon a target or electrode so as to form intact parent monoclonal antibody ions, intact minus light chain parent monoclonal antibody ions or light chain (“LC”) fragment monoclonal antibody ions.

Methods and system for identifying and/or quantifying a protein are provided herein.

A system for detecting an infection caused by a strain of bacteria, the system comprising an electrode functionalised with proteins isolated from a cell wall of a bacteria of the strain of bacteria and a controller configured to communicate with the electrode to perform an electrochemical test of a blood sample from a subject. The blood binding sites of proteins to bacteria cell wall to sample deposited on the electrode, wherein the electrochemical test measures a binding energy of one or more biomarkers in the blood sample with the proteins functionalised on the electrode to determine whether the subject has or has had an immune response to the strain of bacteria indicative of an infection caused by the strain of bacteria.

Described herein are materials and methods of incorporating CLIP peptide into the peptide binding groove of HLA Class II antigens and using such HLA Class II antigens for the detection of alloantibodies.

This disclosure provides a novel label-free N-glycan analysis method to detect and quantify N-glycans and N-linked glycosylation profiles without using a label, such as a fluorescent label. This method allows for reduced sample preparation and chromatographic separation times, and can be used for product batch release.

The present invention generally pertains to methods of quantitating therapeutic proteins co-administered to a subject using LC-MRM-MS. In particular, the present invention pertains to the use of dual enzymatic digestion to generate unique surrogate peptides allowing for the accurate quantitation of co-administered therapeutic proteins using LC-MRM-MS.